Rabeprazole sodium is one of the most effective proton pump inhibitor, belongs to the group of benzimidazole, used against peptic ulcer disease to suppress excess acid secretion in the stomach. Benzimidazoles are antiulcerous compounds known for decreasing gastric acid secretion. Thesecompounds, also known as Proton Pump Inhibitors (PPIs) are commonly indicated for the treatment ofGERD (Gastro Esophageal reflux Disease), Pathological Hypersecretory conditions (Zollinger ‐ Ellison). It is a challenging drug due to its sensitivity to excipients or environmental variables such as light, high temperatures, acidic or basic conditions, humidity, and oxidative environment. Due to its acid-labile nature, the medication is designed as an enteric-coated dose form, like most other PPIs. The purpose of this study was to investigate the formulation development, stability and enteric performance of Rabeprazole sodium (Na) tablets coated with a hypromellose phthalate based enteric coating system. Acid labile PPI may further decompose if it is coated with enteric coating acidic substance. This restriction was overcame by coating the core of the device